Gardasil News and Research

RSS

Gardasil is a vaccine that prevents the types of genital human papillomavirus (HPV) that cause most cases of cervical cancer and genital warts. The vaccine, Gardasil, is given in three shots over six-months. The vaccine is routinely recommended for 11 and 12 year old girls. It is also recommended for girls and women age 13 through 26 who have not yet been vaccinated or completed the vaccine series.

HPV vaccination does not affect rate of disease flares in patients with SLE, study finds

Results of a Chinese study showed that the HPV vaccine did not have significant effects on the number of disease flares or antibody measures in patients with inactive SLE receiving stable doses of medications after administration, and therefore was determined safe to use to prevent HPV in this group of patients.

26 May 2011

New GARDASIL data against Human Papillomavirus presented at EUROGIN conference

A real-world study evaluating the safety of GARDASIL among 189,629 females in California found no serious adverse events related to vaccination, no safety signals for any health event resulting in an emergency room visit or hospitalization and no safety signals associated with pre-specified autoimmune conditions or pregnancy outcomes.

9 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

Rwandan First Lady Jeannette Kagame on Tuesday, in collaboration with two companies, launched a national cervical cancer vaccination and screening program, the first of its kind in Africa, the New Times reports.

27 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

TCI forecasts cancer vaccine market to approach $3 billion in 2015

Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

20 Apr 2011

Cervical cancer vaccine target falls short: Report

Data from the Australian federal government shows that the target to immunize 80 per cent of 12-year-old girls against cervical cancer is not being met because many of them are failing to have all three doses of the vaccine. This potentially undermines the effectiveness of the $436 million program started in 2007.

19 Apr 2011

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

International experts gather in Prague today for a three day meeting focused on the impact of vaccines on public health, at a time of increasing concern that public scepticism and complacency could undermine the positive impact of current and future vaccine campaigns.

31 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

Australia’s top scientist takes on top job

Today, the man who is known for one of Australia’s greatest medical achievements – the development of a cervical cancer vaccine – has been appointed as Chief Executive Officer of the Translational Research Institute (TRI) in Brisbane, Queensland.

23 Feb 2011

Oral sex linked to cancer

Researchers from the United States have said that there is strong evidence linking oral sex to cancer. They have urged more study of how human papillomaviruses may be to blame for a rise in oral cancer among white men.

20 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

bioMD makes offer for Allied Medical

bioMD Limited (ASX: BOD), a company with assets in regenerative tissue engineering technologies today announced that it has made an offer to buy all of the shares in Allied Medical Limited (Allied), a public unlisted company that specialises in the sales, distribution and commercialisation of medical technologies.

14 Feb 2011

Anti-cancer shots for boys in the pipeline

The Pharmaceutical Benefits Advisory Committee (PBAC) is deciding on whether to include the human papillomavirus (HPV) vaccine, Gardasil in in the National Immunization Program for boys.

8 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Offensive protein generated by HPV handicaps defensive protein made by the human body

An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

12 Jan 2011

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Men are more willing to receive human papillomavirus vaccine when they learn the vaccine can prevent cancer, according to a recent University of North Carolina at Chapel Hill study.

5 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010